Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Moreau, Philippe" or (type any "bookEditor issueEditor" and editor="Moreau, Philippe")

Add to list
- Conference Paper
- open access
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial

Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Michel Attal, Fritz Offner (UGent) , Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, et al.

(2020) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 20. p.S307-S308
Add to list
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

Meletios A. Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, et al.

(2019) LANCET. 393(10168). p.253-264
Add to list
- Conference Paper
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Andrew J. Yee, Carol Ann Huff, Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Philippe Moreau, David Dingli, Craig E. Cole, Sagar Lonial, et al.

(2019) BLOOD. 134.
Add to list
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

Xavier Leleu, Guillemette Fouquet, Valentine Richez, Stephanie Guidez, Alain Duhamel, Francois Machuron, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, et al.

(2019) CLINICAL CANCER RESEARCH. 25(14). p.4224-4230
Add to list
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew J. Yee, Carol A. Huff, Philippe Moreau, David Dingli, Craig Cole, Sagar Lonial, et al.

(2019) NEW ENGLAND JOURNAL OF MEDICINE. 381(8). p.727-738
Add to list
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Ludek Pour, Roman Hájek, Thierry Facon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, et al.

(2016) LANCET ONCOLOGY. 17(1). p.27-38
Add to list
- Conference Paper
- C3
IFM2012-03

Xavier Leleu, Guillemette Fouquet, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jv Malfuson, Pascal Bourquard, Pascal Lenain, et al.

(2016) BLOOD. 128(22).
Add to list
- Conference Paper
- C3
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Xavier Leleu, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Thierry De Revel, Pascal Bourquard, Pascal Lenain, Murielle Roussel, et al.

(2015) BLOOD. 126(23).

Academic Bibliography

Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

IFM2012-03

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Contents

Support

Contact